Positive correlation was observed between NAT10 vs. SLC7A11 (r = 0.42; p = 1.4 × 10−8) and NAT10 vs. GCLC (r = 0.33; p = 1.5 × 10−5), suggesting that both SLC7A11 and GCLC interact with NAT10 in breast cancer patients and, therefore, NAT10 is a promising candidate to target ferroptosis in breast cancer patients (Figure 8A). This evidence concerns the gene SLC7A11 and breast carcinoma.